Constellation Alpha Capital Corp

Constellation Alpha Capital — DermTech — Investor Presentation (January 2020)

23 slides from Constellation Alpha Capital's investor presentation, Jan 30, 2020

  1. Slide 1: Corporate Presentation Q1 2020

    Corporate PRESENTATION q1 2020 Exhibit 99.1

  2. Slide 2: Forward-looking statements

    This presentation includes forward-looking statements intended to qualify for the Safe Harbor from liability established by the Private Securities Litigation Reform Act of 1995. Forward-looking statements include all statements that are not historical facts and can be identified by terms such as “an

  3. Slide 3: Leadership Team

    Leadership Team John Dobak, MD Chief Executive Officer Todd Wood Chief Commercial Officer Kevin Sun, MS, MBA Chief Financial Officer Zuxu Yao, PhD Chief Scientific Officer Burkhard Jansen, MD Chief Medical Officer Claudia Ibarra Chief Operating Officer Founder & Chairman, 10xBio (aesthetic medicine

  4. Slide 4: DermTech: leader in precision dermatology

    DermTech, Inc. (NASDAQ: DMTK) is a leader in precision dermatology enabled by a non-invasive skin genomics platform. DERMTECH Mission: To bring precision to the practice of dermatology through non-invasive genomic assessment of the skin. We address very large market opportunities in skin cancer and

  5. Slide 5: Genomic Innovations Are Less Invasive, More Accurate, Less Expensive

    Genomic Innovations Are Less Invasive, More accurate, and less expensive Focus COMPANY OLD STANDARD OF CARE NEW-GEN DIAGNOSTIC Breast Colorectal Thyroid Heart Lung Prenatal Skin

  6. Slide 6: Skin Cancer

    Skin Cancer Melanoma, Basal Cell, and Squamous Cell Carcinoma More people are diagnosed with skin cancer than all other cancers combined and 1 in 5 Americans will develop skin cancer by the age of 70 A Snapshot of the U.S. Skin Cancer Market Annual cost of treatment is estimated to be $8.1 billion,

  7. Slide 7: Early Detection of Melanoma Is Critical to Survival

    When Diagnosed at the Local Stage 98% When Diagnosed at the Regional Stage 64% When Diagnosed at the Distant Stage 23% 1. Cancer Facts & Figures 2018. American Cancer Society. 2. Hanke CW, Carcinoma and Keratoses, 1:2 2019 Not Skin Cancer Skin Cancer Not Skin Cancer Skin Cancer 5-Year Relative Survi

  8. Slide 8: Subjective Pathology Assessment: Current Standard of Care Is Antiquated

    Subjective Pathology Assessment Current Standard of Care in melanoma is Antiquated Anderson A, et al., JAMA Dermatology, 2018; doi:10.1001/jamadermatol.2018.0212 Elmore JG, et al. BMJ. 2017;357:j2813. Strazzula L, et al. Journal of the American Academy of Dermatology, 2014; 71:1071-6 Most Biopsies A

  9. Slide 9: PLA Brings Skin Cancer Diagnostics into the 21st Century

    PLA Brings Skin cancer diagnostics into the 21st century A Better Diagnostic Solution for Dermatology Subjective Visual Assessment Surgical Biopsy Subjective Histopathology Adhesive Patch Sample Collection Genomic Analysis CLIA/CAP Commercial Lab Physician Report (within 72 hrs.) SUBJECTIVE LOW ACCU

  10. Slide 10: Pigmented Lesion Assay (PLA)

    Genomic Material Purified from Patch Enhanced Early Melanoma Detection: Non-invasive Gene Expression Test1 Dermtech’s pigmented lesion assay (pla) Non-invasive adhesive patch collection Avoids unnecessary surgery Improved patient care Highly accurate Low probability of missed melanoma (<1%) 100% of

  11. Slide 11: Better Care at a Lower Cost

    Better care at a lower cost Performance Metric Biopsy & Histology PLA Test Improvement Probability Of Missed Melanoma1 17% 1% 17x Biopsies Per Melanoma2 25 2.7 10x Wide Excisions Per Melanoma2,3 5.2 1.6 3x Cost Per Lesion Tested4 ~$1,000 $760 -$240 Fewer biopsies while missing fewer melanomas A long

  12. Slide 12: Strong Clinical Validation and Robust IP Portfolio

    Strong clinical Validation and Robust IP Portfolio MILESTONE STATUS SAMPLE SIZE Analytical Validation ✔ Complete 125 Clinical Validation – pathology ✔ Complete 555 Clinical Validation – mutation ✔ Complete 626 Clinical Utility ✔ Complete 45 Derms Real-World Utility ✔ Complete 381 1-Year Follow-up ✔

  13. Slide 13: CMS Pricing Unlocks Significant Market Opportunity

    Source: IQVIA Skin Cancer Claims and Procedures Study 2020 Clinical Laboratory Fee Schedule: https://www.cms.gov/medicaremedicare-fee-service-paymentclinicallabfeeschedclinical-laboratory-fee-schedule-files/20clabq1 CMS pricing in place unlocks Significant Market Opportunity ~2.0 Million Total Biops

  14. Slide 14: PLA Case Study – JAMA Dermatology Publication

    Effectiveness Attributes of the PLA Test Background DermTech Results 28-year-old female Family history of melanoma Complained of bug bite Refused surgical biopsy PLA test was positive Histopathology revealed 0.5-mm melanoma Curative wide excision performed Case study published in JAMA Dermatology1 1

  15. Slide 15: Commercial Activities

    COMMERCIAL ACTIVITIES

  16. Slide 16: Commercial Growth Strategy

    Commercial Growth Strategy 1 Establish broader payer coverage Leverage new Medicare coverage to Medicare Advantage plans and commercial payers 2 Drive adoption through optimized clinician messaging Improved and tested professional campaign Actively engage and mobilize the patient Scale our digital p

  17. Slide 17: U.S. Field Sales Territory Map

    = Target HCP Color = sales territory Each circle represents a prioritized dermatology target: high number melanoma biopsies, >50% proportion Medicare patients Penetrate 80% of ~4,6541 target Derm HCPs Average ~66 biopsies/mo/clinician Drive to average of 10 PLA tests/mo/clinician2 Based on historica

  18. Slide 18: PLA Enhances the Current Standard of Care

    PLA Test Biopsy VS Samples the entire lesion Provides additional objective genomic information Measures malignant changes that cannot be seen visually Samples less than 1-2% of a potentially partial surgical biopsy Relies on subjective visual criteria Morphologic changes must be present and in the f

  19. Slide 19: Improved Practice Efficiency and Patient Capacity

    Improved Practice Efficiency and Patient Capacity Ambiguous lesions photographed and followed-up Most atypical/obvious lesion Patient With Multiple Pigmented Lesions Physician Billing Biopsy Procedure Code 11300 Physician Billing Level 4 E&M Code 992141 Surgical Biopsy PLA Define PLA Positioning and

  20. Slide 20: Scale Digital Consumer Campaign

    Successful Facebook pilot exceeded reach and click-through rates2 Consumer research shows patients frustrated with current care and are vocal about it1 *West Health Institute Survey on Aging America, 2016 of adults 60 and older have health plan coverage* 97% of adults 60-69 rate health and wellness

  21. Slide 21: Medicare Coverage: A Significant Milestone for Test Unit and Revenue Growth

    Source: DermTech, Inc., Capital IQ, Bloomberg Medicare Coverage A Significant Milestone for Test Unit and Revenue Growth DermTech Quarterly Billable Sample Volume, 2019 Company Test CMS Approval Pre-Approval Revenue (MM) Year 1 Revenue (MM) Year 1 Gross Margin Year 1 Opex % Rev Exact Sciences Cologu

  22. Slide 22: Product and Research Partnership Pipeline

    LINC: Long Intergenic Non-protein Coding RNA 518; PCR: Polymerase Chain Reaction; Mut: Mutation; PRAME: Preferentially Expressed Antigen in Melanoma; R/O: Rule Out; Tx: Treatment; TERT: Telomerase Reverse Transcriptase Product and research Partnership Pipeline Product Test Purpose Assay Type Gene Ta

  23. Slide 23: Commercial Lab Operations

    Commercial Lab Operations CLIA-licensed laboratory in State of California and all states requiring out-of-state licensure CAP-accredited ~9000-square-foot commercial lab space Current capacity 50,000 tests per year Adding automation to increase to 100k+/year Expansion preparation to 500k/year PLA as

DermTech — Investor Presentation (January 2020) on 6ix